ANGLE device yields positive results in Athens head and neck cancer study

The data showed its liquid biopsy to be superior to a leading antibody approach at harvesting circulating tumour cells 


ANGLE PLC (LON:AGL OTCQX:ANPCY) said a study by the University of Athens showed its liquid biopsy was superior to a leading antibody approach when it came to harvesting circulating tumour cells (CTC) in people with head and neck cancer.

Researchers drew blood from 50 patients and 18 healthy volunteers. The published data revealed use of the ANGLE technology resulted in much higher CTC harvesting positivity rates, purer samples, and “excellent” RNA quality for molecular analysis.

The UK med-tech company’s approach also delivered “higher relative expression levels” for key cancer genes, including PDL1, which is a target for immunotherapy drugs used for this type of cancer.

The Athens team also found a significantly higher proportion of samples tested positive for what are called DNA methylation markers, which could help the early detection of the disease.

In a statement, ANGLE chief executive Andrew Newland said: “Head and neck cancer represents a large-scale medical opportunity for the repeat deployment of ANGLE's Parsortix liquid biopsy solution, with the potential to both improve the patient outcome and simultaneously reduce spend on unsuccessful drugs."

Head and neck cancer is the sixth most common cancer in the world, with 550,000 cases a year and 300,000 deaths. Five-year survival rates are 40-50%.

Quick facts: ANGLE PLC

Price: 48.5 GBX

Market: AIM
Market Cap: £835.9 k

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read